CD300E Lentiviral Activation Particles (h): sc-415572-LAC

CD300E (also known as IREM-2) encodes an immunoglobulin superfamily receptor primarily expressed on myeloid lineage cells, where it modulates innate immune activation and inflammatory signaling. Engagement of CD300E can couple to adaptor-dependent pathways that promote cellular activation programs, including cytokine production, phagocytic responses, and antigen-presenting cell maturation, intersecting with NF-κB and MAPK-associated processes. Altered regulation of myeloid receptor signaling is relevant to immune dysregulation states and inflammatory disease biology, and CD300E expression patterns are frequently evaluated in studies of leukocyte activation and tissue immune microenvironments. As a cell-surface immunoreceptor, CD300E is also useful for dissecting how activating receptor networks shape macrophage and dendritic cell functional polarization.

CD300E Lentiviral Activation Particles (h) address this need by packaging the complete synergistic activation mediator (SAM) transcriptional activation system into transduction-ready, high-titer lentiviral particles, enabling efficient CD300E upregulation across a broader range of human cell types.

CD300E Lentiviral Activation Particles (h) deliver all functional components of the synergistic activation mediator (SAM) system via lentiviral transduction. The system comprises three particle preparations co-transduced into target cells: one encoding catalytically inactive dCas9 (D10A and N863A mutations) fused to the VP64 transactivation domain with a blasticidin resistance gene; one encoding the MS2-p65-HSF1 fusion protein with a hygromycin resistance gene; and one encoding a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers with a puromycin resistance gene. Following lentiviral transduction and genomic integration of the expression cassettes, the SAM components are stably expressed and assemble at the target locus within the proximal promoter region upstream of the CD300E transcriptional start site, where VP64, p65, and HSF1 act cooperatively to recruit endogenous transcriptional machinery and drive sustained upregulation of endogenous CD300E expression. The use of nuclease-inactive dCas9 avoids the introduction of double-strand DNA breaks and preserves the native CD300E genomic locus and regulatory architecture.

The lentiviral format offers several practical advantages: stable genomic integration supports heritable activation across cell divisions; high-titer particle preparations eliminate the need for in-house viral production; and compatibility with primary, non-dividing, and transfection-resistant cell types expands experimental accessibility. Successful transduction can be confirmed and enriched through triple antibiotic selection using puromycin, hygromycin, and blasticidin.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.